Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs88.21 M102.8 M102.46 M76.16 M72.98 M73.54 M71.43 MRecherche et développement266.95 M438.63 M461.64 M387.33 M320.65 M284.81 M280.9 MRésultat d'exploitation-354.44 M373.53 M-673.16 M-222.54 M-466.57 M-664.57 M-646.39 MTotal des produits hors exploitation6.38 M6 M22.66 M71.82 M103.9 M86.61 M81.22 MCharges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts000000-553 KRevenus/dépenses exceptionnels6.38 M6 M22.66 M71.82 M103.9 M86.61 M81.22 MRésultat avant impôts-348.06 M379.53 M-650.5 M-150.72 M-362.67 M-577.97 M-565.17 MPart des actionnaires dans le résultat-5.47 M-5.47 M—————Impôts809 K1.87 M-325 K2.89 M3.59 M3.63 M3.36 MIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts-1.86 M—-12.47 M16.55 M38.62 M23.53 M16.98 MRésultat net avant activités abandonnées-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-568.53 MActivités abandonnées———————Résultat net-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-568.53 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-568.53 MBénéfice par action de base (BPA de base)-5.294.97-8.36-1.94-4.34-6.47-6.17Bénéfice par action dilué (BPA dilué)-5.294.7-8.36-1.94-4.34-6.47-6.17Nombre moyen d'actions de base en circulation65.95 M75.95 M77.75 M79.22 M84.36 M89.93 M—Nombre d'actions en circulation après dilution65.95 M80.39 M77.75 M79.22 M84.36 M89.93 M—EBITDA-345.25 M391.48 M-648.99 M-202.7 M-447.31 M-645.09 M-627.33 MEBIT-354.44 M373.53 M-673.16 M-222.54 M-466.57 M-664.57 M-646.39 MCoût des ventes———————Autres coûts des ventes———————Amortissements (flux de trésorerie)9.18 M17.95 M24.17 M19.84 M19.26 M19.48 M19.06 M
CRISPR Therapeutics AG - Common Shares
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.